PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in PharmaCyte Biotech, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +3 vs. Q4 2024
- Shares held
- 568.2K
- −32.6K (−5.4%) vs. Q4 2024
- Total value
- $709.9K
- −$224.4K (−24.0%) vs. Q4 2024
- New holders
- 4
- 4 more added
- Sold out
- 1
- 8 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PMCB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 32 | $586.2K |
| Q1 2026 | 36 | $643.2K |
| Q4 2025 | 30 | $712.0K |
| Q3 2025 | 25 | $419.9K |
| Q2 2025 | 25 | $632.1K |
| Q1 2025 | 26 | $709.9K |
| Q4 2024 | 23 | $934.3K |
| Q3 2024 | 29 | $1.58M |
| Q2 2024 | 32 | $2.02M |
| Q1 2024 | 33 | $2.32M |
| Q4 2023 | 36 | $2.35M |
| Q3 2023 | 34 | $2.40M |
| Q2 2023 | 32 | $3.47M |
| Q1 2023 | 33 | $10.2M |
| Q4 2022 | 34 | $9.93M |
| Q3 2022 | 33 | $12.0M |
| Q2 2022 | 35 | $8.79M |
| Q1 2022 | 28 | $8.83M |
| Q4 2021 | 30 | $8.68M |
| Q3 2021 | 24 | $4.42M |
| Q2 2021 | 5 | $5.43K |
| Q1 2021 | 5 | $8.68K |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding PharmaCyte Biotech, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 194,518 | $243.1K | 0.00% | +2,131+1.1% | Added |
| Geode Capital Management, LLC | 138,935 | $173.7K | 0.00% | −25,801−15.7% | Reduced |
| Equitec Proprietary Markets, LLC | 82,727 | $103.4K | 0.30% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 49,500 | $61.9K | 0.00% | +200+0.4% | Added |
| Schonfeld Strategic Advisors LLC | 25,500 | $31.9K | 0.00% | −200−0.8% | Reduced |
| Dimensional Fund Advisors LP | 20,299 | $25.4K | 0.00% | −6,542−24.4% | Reduced |
| Northern Trust Corp | 19,208 | $24.0K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 18,406 | $23.0K | 0.00% | −16,075−46.6% | Reduced |
| UBS Group AG | 11,916 | $14.9K | 0.00% | +10,042+535.9% | Added |
| Tower Research Capital LLC (TRC) | 3,438 | $4.30K | 0.00% | +993+40.6% | Added |
| National Bank of Canada | 3,300 | $4.09K | 0.00% | +3,300 | New |
| Bank of America Corp | 73 | $92 | 0.00% | −5−6.4% | Reduced |
| Park Square Financial Group, LLC | 37 | $46 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 16 | $20 | 0.00% | −2−11.1% | Reduced |
| Sachetta, LLC | 14 | $18 | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 14 | $18 | 0.00% | +14 | New |
| Advisor Group Holdings, Inc. | 10 | $12 | 0.00% | −527−98.1% | Reduced |
| FMR LLC | 6 | $8 | 0.00% | +6 | New |
| BFSG, LLC | 5 | $7 | 0.00% | 00.0% | Unchanged |
| Caldwell Sutter Capital, Inc. | 2 | $3 | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 2 | $3 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1 | $2 | 0.00% | −1−50.0% | Reduced |
| IFP Advisors, Inc | 1 | $1 | 0.00% | +1 | New |
| Huntington National Bank | 1 | $0 | 0.00% | 00.0% | Unchanged |
| CWM, LLC | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Covestor Ltd | 275 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 0 | $0 | 0.00% | −98−100.0% | Sold out |